mAbxience is a biotechnology company specialising in the research, development and manufacture of biologic products, mainly biosimilar drugs.
Established in Europe in 2009, we are a multinational group that operates internationally and enjoys a strong presence in the major pharmaceutical markets.
mAbxience is also fully committed to high-quality products and processes that meet regulatory and technical requirements in all countries in which we operate.
We currently have two fully developed biosimilars already marketed as well as four in the developmental phase.
Part of the CHEMO Group
mAbxience is part of the Spanish multinational, CHEMO, a group with a strong foundation and a firm investor commitment to all our business activity areas. With over 35 years’ of experience, CHEMO is a group that aims to sustain and improve people’s health and wellbeing, and has a presence at every echelon of the chemical-pharmaceutical industry. Its activities are carried out through three synergistic business areas: industrial, branded and biotechnology. The CHEMO group has a presence in more than 40 countries in Europe, the Americas, Asia and Africa, and is backed up by a network of more than 5,000 professionals, 10 production plants and 9 R&D centres.